Gut microbial signature in lung cancer patients highlights specific taxa as predictors for durable clinical benefit

Stool samples for microbial 16S amplicon sequencing and clinical data were collected from 75 lung cancer patients (50 of which were treated with checkpoint inhibitors) and 31 age-matched healthy volunteers. We compared using multivariate analyses cancer patients to healthy controls, and within lung cancer we compared patients with DCB to those without DCB.